Reviews
Risk-Adapted Treatment and Organ Preservation in Locally Advanced Rectal Cancer: A Narrative Review
Cetin et alJournal of Gastrointestinal Cancer

A narrative review synthesizing evidence from PubMed, Embase, and the Cochrane Library through 31 March 2026, supplemented by source verification in September 2026, evaluated risk-adapted strategies and organ preservation in locally advanced rectal cancer. Treatment selection is guided by magnetic resonance imaging, mismatch repair status, recurrence risk, and patient preferences. Total neoadjuvant therapy is established for higher-risk mismatch repair-proficient/microsatellite-stable disease, whereas selected lower-risk surgical candidates may receive chemotherapy with selective chemoradiation.
Treatment sequencing directly impacts organ preservation: chemoradiation followed by consolidation chemotherapy can improve the probability of organ preservation compared with induction sequencing, though without a demonstrated disease-free survival advantage. Both short-course radiotherapy and long-course chemoradiation remain evidence-based options, and the long-term locoregional failure signal identified in the RAPIDO trial cannot be attributed to fractionation alone.
For organ preservation, watch-and-wait approaches necessitate multimodal confirmation of clinical complete response, intensive surveillance, and reliable access to salvage surgery, as oncological equivalence to immediate resection remains unproven. In mismatch repair-deficient disease, prospective dostarlimab data support non-operative management, while the durability of long-term outcomes requires further evaluation. The authors conclude that clinical management should integrate tumor anatomy, biology, treatment response, and patient priorities, individualizing treatment intensity rather than applying uniform protocols.
Key Takeaways
- Chemoradiation followed by consolidation chemotherapy can improve organ-preservation probability compared with induction sequencing, without a demonstrated disease-free survival advantage.
- The long-term locoregional failure signal reported in the RAPIDO trial cannot be attributed to radiotherapy fractionation alone.
- Prospective dostarlimab data support non-operative management in selected mismatch repair-deficient rectal cancers, though long-term durability requires further evaluation.
Read the original sourceJournal of Gastrointestinal Cancer
